US-first resulted in an incremental net monetary benefit of about $681 versus using diagnostic mammography first, experts wrote in AJR.  

Buzzworthy developments of the past few days. 1. The Federal Trade Commission isn’t messing around.

Patient safety should be the No. 1 consideration for healthcare organizations working, planning or hoping to adopt AI. Then again, nine other concerns are similarly crucial to the success of the industry-wide endeavor.

The organization is teaming up with CereMark Pharma to conduct research on improving outcomes in soldiers and athletes with neurodegenerative conditions.

Individuals are 83% more likely to be diagnosed with a psychiatric disorder within one year of a CVD hospitalization, according to new data published in the Journal of the American Heart Association.

This partnership reflects NextGen Healthcare’s deepening commitment to supporting cardiology practices nationwide. Research shows that nearly 50 percent of adults in the United States have some form of cardiovascular disease today—a rate expected to grow to 61 percent by 2050.

The newly cleared device includes a rapid-exchange catheter and a helical balloon that takes the shape of a hollow cylinder when inflated.

Improving the detection of pulmonary embolism has been a popular target among multiple AI vendors.

A team of Cleveland Clinic specialists tracked data from more than 13,000 patients, focusing on all-cause mortality and long-term cardiovascular outcomes.

The Equitable Community Access to Pharmacist Services Act would allow Medicare to reimburse for certain pharmacist-administered tests, treatments and vaccinations.